Fever Dream

Vaccinologists Keith Klugman and Shabir Madhi Awarded Sabin’s Prestigious Gold Medal; Infectious Diseases Epidemiologist Nicole Basta Receives Rising Star Award

Retrieved on: 
金曜日, 4月 19, 2024

Fueled by an early interest in science as a child in South Africa -- in part due to a physician father – Klugman holds both a medical as well as a science doctorate degree from Wits University and was the first student in the school’s history to obtain them simultaneously. He began his research career nearly five decades ago investigating the typhoid vaccine and has since distinguished himself as a formidable infectious diseases’ scientist. Klugman is widely known for his work on pneumonia, which still kills a child under five every 43 seconds, many in the world’s poorest countries. As the director of the pneumonia program at the Seattle-based Bill and Melinda Gates Foundation, Klugman orchestrates strategic initiatives aimed at reducing deaths from pneumonia, RSV, neonatal sepsis, and meningitis. He has authored hundreds of publications that have been cited over 50,000 times to date and has been elected to the National Academy of Medicine in the United States. Klugman is also a professor emeritus of global health at Atlanta’s Emory University.

Key Points: 
  • Klugman first met his then-graduate student Madhi at South Africa’s University of the Witwatersrand (also known as Wits University), where Klugman established, and Madhi expanded, a now globally renowned infectious diseases research institute.
  • He began his research career nearly five decades ago investigating the typhoid vaccine and has since distinguished himself as a formidable infectious diseases’ scientist.
  • His scientific achievements aside, Klugman has long championed the need for the world’s poorest children to have equitable access to vaccines.
  • Sabin’s Rising Star award was created in 2020 to encourage and recognize the next generation of vaccine and immunization leaders.

Damali Starts Construction on a Hospital in Uganda

Retrieved on: 
火曜日, 4月 30, 2024

SANTA YNEZ, Calif., April 30, 2024 /PRNewswire/ -- Together with Faith of a Child Foundation, Damali Mirembe, the director of the Sonrise Baby Home, recently started construction on a new hospital to serve the Kayunga District of Uganda. The new hospital will include a maternity ward, a pediatric ward, a fully equipped laboratory, emergency care and several in-patient beds.

Key Points: 
  • In an online video , Damali shared her vision for the hospital and explained why she is starting this ambitious project.
  • In 2009, Damali was a young university graduate in Uganda.
  • Immediately, Damali was overwhelmed with the number of abandoned and malnourished babies in Uganda.
  • Damali determined that she must build a new hospital in the rural Kayunga District, to offer better maternity care.

Hyundai Bioscience's antiviral for Dengue Fever to enter clinical trials in Brazil

Retrieved on: 
木曜日, 4月 25, 2024

Hyundai Bioscience decides to conduct dengue clinical trials in Brazil, which has the largest number of Dengue patients and offers a fast-track approval

Key Points: 
  • Hyundai Bioscience decides to conduct dengue clinical trials in Brazil, which has the largest number of Dengue patients and offers a fast-track approval
    SEOUL, South Korea, April 25, 2024 /PRNewswire/ -- Hyundai Bioscience announced on April 25th that, after multiple consultations with global clinical research organizations (CRO), it has decided to conduct clinical trials for its 'niclosamide-based Dengue antiviral' in Brazil, which has the highest number of dengue cases and deaths in the world.
  • Hyundai Bioscience outlined two main reasons for choosing Brazil as its Dengue clinical trial regions:
    Firstly, Brazil has been the most affected country by the Dengue virus.
  • Hyundai Bioscience plans to conduct a basket-type clinical trial in Brazil (confirmatory clinical study for Dengue and exploratory clinical study for other mosquito-borne viral infections).
  • "The success of Dengue clinical study on our Niclosamide-based antiviral could lead to its emergency use authorization not only in Brazil but also in other countries.

EPA Announces Registration of Groundbreaking New Mosquito Control Solution

Retrieved on: 
火曜日, 4月 23, 2024

This new mosquito control pesticide represents a significant advancement in mosquito control.

Key Points: 
  • This new mosquito control pesticide represents a significant advancement in mosquito control.
  • The WB1 pesticide specifically targets the Aedes aegypti mosquito, commonly known as the Yellow Fever mosquito.
  • "This approach offers targeted, species-specific mosquito control for communities and individuals, while maintaining the high safety standards expected by the EPA," Dobson emphasizes.
  • Effective Mosquito Control: WB1 Males effectively target and reduce populations of Aedes aegypti mosquitoes, the primary transmitter of Dengue fever.

Integral Molecular Launches Virus Neutralization Assay Services to Drive Antiviral Discovery

Retrieved on: 
火曜日, 4月 16, 2024

PHILADELPHIA, April 16, 2024 /PRNewswire/ -- Integral Molecular, a leader in providing safe research reagents for virology, announces the launch of its Virus Neutralization Assay Services enabling researchers to rapidly obtain high-quality data to advance their vaccines and therapeutic antibodies.

Key Points: 
  • PHILADELPHIA, April 16, 2024 /PRNewswire/ -- Integral Molecular, a leader in providing safe research reagents for virology, announces the launch of its Virus Neutralization Assay Services enabling researchers to rapidly obtain high-quality data to advance their vaccines and therapeutic antibodies.
  • With over 20 years' experience in virology, Integral Molecular has developed innovative solutions that enable researchers to study viruses safely and efficiently.
  • Integral Molecular's Neutralization Assay Services enable diverse applications:
    Neutralization profiling for antibodies targeting viral proteins.
  • "Our virus research tools have been instrumental in laboratories worldwide, providing safe alternatives to live viruses," said Maya Cabot, PhD, Senior Product Manager at Integral Molecular.

As Public Health Threat of Mosquito-Borne Illness Increases, Florida's World-Class Scientists & Professionals are Ready

Retrieved on: 
月曜日, 4月 15, 2024

Known as the world's deadliest animal, mosquitoes also love Florida, and carry deadly diseases like malaria, West Nile virus, and dengue fever.

Key Points: 
  • Known as the world's deadliest animal, mosquitoes also love Florida, and carry deadly diseases like malaria, West Nile virus, and dengue fever.
  • This week is Florida Mosquito Control Awareness Week , highlighting the incredible science, training and resources dedicated to combating the world's most dangerous animal.
  • Mosquitoes are responsible for more human deaths than any another animal, killing nearly a quarter of a million people globally each year .
  • "It is a true honor to host these passionate, dedicated professionals in Florida," said Dr. Rui-De Xue, AMCD Executive Director.

Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening

Retrieved on: 
木曜日, 4月 4, 2024

These are the four most significant arboviruses of concern, all spread through mosquito vectors.

Key Points: 
  • These are the four most significant arboviruses of concern, all spread through mosquito vectors.
  • With the dengue virus alone, there were more than 5 million cases and 5,000 deaths reported globally in 2023.1
    Further strengthening the Grifols Procleix portfolio for blood donor screening, the Procleix ArboPlex Assay uses plasma or serum samples to detect arboviral RNA.
  • Blood banks and collection centers could decide that deferrals are unnecessary if donors were tested and found negative using the Procleix ArboPlex Assay.
  • “With its 4-in-1 arbovirus test feature, the Grifols Procleix ArboPlex Assay has the ability to speed up and overall improve donor screening laboratory efficiency,” said Antonio Martínez, president of Grifols Diagnostic Business Unit.

Kao and Earth Collaborate in the Field of “Insect (Mosquito) Control” in Thailand

Retrieved on: 
木曜日, 2月 29, 2024

It will be launched in Thailand from July 2024, where Earth has been active domestically for about 40 years.

Key Points: 
  • It will be launched in Thailand from July 2024, where Earth has been active domestically for about 40 years.
  • Earth Corporation founded ARS Chemical (Thailand) Co., Ltd. (now Earth (Thailand) Co., Ltd.) in Thailand in 1980.
  • Earth (Thailand) single-handedly manages development, sales and distribution of, for example, the insect control item brand ARS as a local subsidiary in Thailand.
  • Both Kao and Earth believe that this product will help people living in areas suffering from dengue fever.

Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas

Retrieved on: 
火曜日, 2月 27, 2024

Takeda ( TSE:4502/NYSE:TAK ) and Biological E. Limited (BE), a leading India-based Vaccines and Pharmaceutical Company, today announced a strategic partnership to accelerate access to QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003) multi-dose vials (MDVs).

Key Points: 
  • Takeda ( TSE:4502/NYSE:TAK ) and Biological E. Limited (BE), a leading India-based Vaccines and Pharmaceutical Company, today announced a strategic partnership to accelerate access to QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003) multi-dose vials (MDVs).
  • These doses will ultimately be made available for procurement by governments in endemic countries by 2030 at the latest to support National Immunization Programs.
  • MDVs offer economic and logistical advantages for National Immunization Programs by minimizing packaging and storage expenses, while also reducing medical and environmental waste.
  • Together, we will help combat dengue on a global scale by significantly increasing manufacturing capacity for multi-dose vials of QDENGA to drive sustainable access to the vaccine in more endemic countries."

Co-Diagnostics, Inc. JV CoSara Receives Clearance from Indian Regulators for Influenza Multiplex PCR Test

Retrieved on: 
木曜日, 3月 7, 2024

SALT LAKE CITY, March 7, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that CoSara Diagnostics Pvt Ltd ("CoSara," or the "JV"), its joint venture for manufacturing and sales in India, has received clearance by the Central Drugs Standard Control Organization ("CDSCO") in India to manufacture and sell its SARAPLEX™ Influenza Multiplex (IFM) Test Kit to clinical laboratories as an in vitro diagnostic ("IVD") for the detection and differentiation of Influenza A and Influenza B.

Key Points: 
  • Co-Primers utilize a unique design architecture to combat common issues with real-time PCR that can lead to inaccurate results, specifically primer dimer propagation, and which are magnified in multiplex reactions.
  • "The importance of accurate, reliable PCR testing at the high-throughput clinical laboratory level remains critical," remarked Dwight Egan, CEO of Co-Diagnostics.
  • *The Co-Dx PCR platform (including the PCR Home™, PCR Pro™, mobile app, and all associated tests) is subject to review by the FDA and/or other regulatory bodies and is not yet available for sale.
  • The Co-Dx PCR Pro instrument and Co-Dx COVID-19 Test are currently under review by the FDA.